{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hao M"],"funding":["\"Open Competition to Select the Best Candidates\" Key Technology Program for Nucleic Acid Drugs of NCTIB","Fundamental Research Funds for the Central Universities of China (Nanjing University of Science and Technology)","Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University)","Double First-Class University project","National Natural Science Foundation of China","Fundamental Research Funds for the Central Universities of China (China Pharmaceutical University)","National Major Scientific and Technological Special Project for \"Significant New Drugs Development\"","Natural Science Foundation of Jiangsu Province"],"pagination":["e2401100"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11220647"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(25)"],"pubmed_abstract":["Due to multidimensional complexity of solid tumor, development of rational T-cell combinations and corresponding formulations is still challenging. Herein, a triple combination of T cells are developed with Indoleamine 2,3-dioxygenase inhibitors (IDOi) and Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). To maximize synergism, a spatiotemporally controlled T-cell engineering technology to formulate triple drugs into one cell therapeutic, is established. Specifically, a sequentially responsive core-shell nanoparticle (SRN) encapsulating IDOi and CDK4/6i is anchored onto T cells. The yielded SRN-T cells migrated into solid tumor, and achieved a 1st release of IDOi in acidic tumor microenvironment (TME). Released IDOi restored tryptophan supply in TME, which activated effector T cells and in"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Spatiotemporally Controlled T-Cell Combination Therapy for Solid Tumor."],"pmcid":["PMC11220647"],"funding_grant_id":["2019ZX09301163","82130102","NCTIB2022HS01014","92159304","2632023TD01","82104102","SKLNMKF202206","BK20220140","81930099","CPU2022QZ05","BK20230104","30921011220","81773664","22175091","SKLNMZZ202223","BK20212011","SKLNMZZ202310","82373823"],"pubmed_authors":["Shen M","Li W","Li X","Hao M","Xue L","Zhou Y","Chen S","Jin Y","Zhang C"],"additional_accession":[]},"is_claimable":false,"name":"Spatiotemporally Controlled T-Cell Combination Therapy for Solid Tumor.","description":"Due to multidimensional complexity of solid tumor, development of rational T-cell combinations and corresponding formulations is still challenging. Herein, a triple combination of T cells are developed with Indoleamine 2,3-dioxygenase inhibitors (IDOi) and Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). To maximize synergism, a spatiotemporally controlled T-cell engineering technology to formulate triple drugs into one cell therapeutic, is established. Specifically, a sequentially responsive core-shell nanoparticle (SRN) encapsulating IDOi and CDK4/6i is anchored onto T cells. The yielded SRN-T cells migrated into solid tumor, and achieved a 1st release of IDOi in acidic tumor microenvironment (TME). Released IDOi restored tryptophan supply in TME, which activated effector T cells and in","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T23:54:55.401Z","creation":"2025-04-04T23:54:55.401Z"},"accession":"S-EPMC11220647","cross_references":{"pubmed":["38634209"],"doi":["10.1002/advs.202401100"]}}